Latest On BioCardia, Inc (BCDA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-30 11:41 EST | News | BioCardia: An Update And A Near-Term Catalyst (Rating Downgrade) | N/A |  |
| 2023-05-11 02:25 EST | News | BioCardia GAAP EPS of -$0.17 in-line | N/A | |
| 2023-05-11 02:25 EST | News | BioCardia, Inc. (BCDA) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-03-30 01:18 EST | News | BioCardia GAAP EPS of -$0.67 misses by $0.02, revenue of $1.4M beats by $1.35M | N/A | |
| 2023-03-30 01:18 EST | News | BioCardia, Inc. (BCDA) Q4 2022 Earnings Call Transcript | N/A | |
About BioCardia, Inc (BCDA):
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
General
- Name BioCardia, Inc
- Symbol BCDA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 20
- Last Split Factor1:9
- Last Split Date2019-06-06
- Fiscal Year EndDecember
- IPO Date2008-03-14
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.biocardia.com
Valuation
- Price/Sales (Trailing 12 Mt.) 124.13
- Price/Book (Most Recent Quarter) 16.15
- Enterprise Value Revenue 191.96
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.28
- Operating Margin -4957%
- Return on Assets -96%
- Return on Equity -333%
- Revenue 314000
- Earnings Per Share -$3.20
- Revenue Per Share $0.04
- Gross Profit -8210000
- Quarterly Earnings Growth -82.5%
Highlights
- Market Capitalization 62.93 million
- EBITDA -14587000
- Analyst Target Price $10.63
- Book Value Per Share $0.33
Share Statistics
- Shares Outstanding 14.47 million
- Shares Float 7.47 million
- % Held by Insiders 4290%
- % Held by Institutions 14.56%
- Shares Short 217287
- Shares Short Prior Month 216158
- Short Ratio 0.56
- Short % of Float 2%
- Short % of Shares Outstanding 2%
Technicals
- Beta 2.07
- 52 Week High $6.5
- 52 Week Low $1.91
- 50 Day Moving Average 4.29
- 200 Day Moving Average 3.16
Dividends
- Dividend Date 2019-06-06
- ExDividend Date N/A
- Dividend Yield 0%
BioCardia, Inc (BCDA) Dividend Calendar:
BCDA's last dividend payment was made to shareholders on June 6, 2019.
BioCardia, Inc (BCDA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
BioCardia, Inc (BCDA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
BioCardia, Inc (BCDA) Chart:
BioCardia, Inc (BCDA) News:
Below you will find a list of latest news for BioCardia, Inc (BCDA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
BioCardia, Inc (BCDA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest BCDA Trades:
BioCardia, Inc (BCDA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-27 | 8-K (Current report) | |
| 2020-10-20 | EFFECT (Notice of Effectiveness) | |
| 2020-10-09 | 8-K (Current report) | |
| 2020-10-09 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-10-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-13 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-13 | 8-K (Current report) | |
| 2020-07-07 | 8-K (Current report) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
BioCardia, Inc (BCDA) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of BioCardia, Inc (BCDA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 4290%
Institutional Ownership: 1456%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-02 | Eric Duckers | Chief Medical Officer | Sell | 8,435.00 | 2.01 | 16,954.35 | 12,088.00 | |
| 2020-09-30 | Andrew Scott Blank | Director | Buy | 4,843.00 | 134,797.00 | | ||
| 2020-09-30 | SIMON H STERTZER | Director | Buy | 2,968.00 | 195,482.00 | | ||
| 2020-09-30 | RICHARD M KRASNO | Director | Buy | 2,734.00 | 38,629.00 | | ||
| 2020-09-30 | FERNANDO L FERNANDEZ | Director | Buy | 2,968.00 | 40,644.00 | | ||
| 2020-09-30 | JAY M MOYES | Director | Buy | 3,750.00 | 44,261.00 | | ||
| 2020-09-30 | RICHARD C JR PFENNIGER | Director | Buy | 3,125.00 | 46,045.00 | | ||
| 2020-09-30 | Jim L. Allen | Director | Buy | 2,734.00 | 673,668.00 | | ||
| 2020-06-30 | Andrew Scott Blank | Director | Buy | 3,281.00 | 129,954.00 | | ||
| 2020-06-30 | SIMON H STERTZER | Director | Buy | 4,531.00 | 192,514.00 | | ||
| 2020-06-30 | RICHARD M KRASNO | Director | Buy | 2,734.00 | 35,895.00 | | ||
| 2020-06-30 | FERNANDO L FERNANDEZ | Director | Buy | 2,968.00 | 37,676.00 | | ||
| 2020-06-30 | JAY M MOYES | Director | Buy | 3,750.00 | 40,511.00 | | ||
| 2020-06-30 | RICHARD C JR PFENNIGER | Director | Buy | 3,125.00 | 42,920.00 | | ||
| 2020-06-30 | Jim L. Allen | Director | Buy | 2,734.00 | 670,934.00 | | ||
| 2020-06-19 | Andrew Scott Blank | Director | Buy | 142,850.00 | 2.10 | 299,985.00 | 142,850.00 | |
| 2020-06-19 | SIMON H STERTZER | Director | Buy | 142,850.00 | 2.10 | 299,985.00 | 187,983.00 | |
| 2020-06-19 | Jim L. Allen | Director | Buy | 142,850.00 | 2.10 | 299,985.00 | 668,200.00 | |
| 2020-05-08 | Andrew Scott Blank | Director | Buy | 4,100.00 | 126,673.00 | | ||
| 2020-05-08 | RICHARD M KRASNO | Director | Buy | 8,800.00 | 33,161.00 | |